Histogenics Corp (NASDAQ:HSGX) saw a large increase in short interest during the month of October. As of October 31st, there was short interest totalling 4,746,237 shares, an increase of 204.3% from the October 15th total of 1,559,679 shares. Based on an average daily trading volume, of 9,592,913 shares, the short-interest ratio is presently 0.5 days. Approximately 31.6% of the shares of the company are short sold.
Several hedge funds and other institutional investors have recently made changes to their positions in HSGX. BlackRock Inc. lifted its holdings in shares of Histogenics by 72.0% in the 2nd quarter. BlackRock Inc. now owns 54,753 shares of the biotechnology company’s stock worth $137,000 after purchasing an additional 22,927 shares during the last quarter. DRW Securities LLC bought a new stake in shares of Histogenics in the 2nd quarter worth approximately $242,000. JPMorgan Chase & Co. bought a new stake in shares of Histogenics in the 1st quarter worth approximately $320,000. Finally, Renaissance Technologies LLC lifted its holdings in shares of Histogenics by 6.1% in the 2nd quarter. Renaissance Technologies LLC now owns 384,329 shares of the biotechnology company’s stock worth $961,000 after purchasing an additional 22,133 shares during the last quarter. 45.88% of the stock is currently owned by institutional investors and hedge funds.
A number of research firms have commented on HSGX. Zacks Investment Research downgraded Histogenics from a “buy” rating to a “hold” rating in a report on Thursday, August 16th. HC Wainwright reaffirmed a “buy” rating and set a $3.50 target price on shares of Histogenics in a report on Monday, August 13th. Brookline Cap M reaffirmed a “buy” rating on shares of Histogenics in a report on Wednesday, August 1st. Needham & Company LLC increased their target price on Histogenics to $5.00 and gave the stock a “buy” rating in a report on Thursday, September 6th. Finally, BTIG Research downgraded Histogenics from a “buy” rating to a “neutral” rating and set a $3.50 price target on the stock. in a report on Wednesday, September 5th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. Histogenics currently has a consensus rating of “Hold” and a consensus target price of $3.25.
Histogenics (NASDAQ:HSGX) last announced its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.05). On average, analysts forecast that Histogenics will post -0.83 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Histogenics Corp (HSGX) Short Interest Update” was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://sportsperspectives.com/2018/11/10/histogenics-corp-hsgx-short-interest-update.html.
Histogenics Company Profile
Histogenics Corporation, a clinical-stage company, focuses on the development of restorative cell therapies in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
Further Reading: Insider Trading – What You Need to Know
Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.